The Asia-Pacific companion diagnostics market is predicted to register a CAGR of 13.55% during the forecast period of 2022 to 2030. Key factors such as the rise in healthcare awareness, collaborations between diagnostic companies, the pharmaceutical industry, regulatory authorities, and service providers to provide an international platform, and the significant development in precision medicine technology are primarily ascribed to the region’s market growth.
MARKET INSIGHTS
The Asia-Pacific companion diagnostics market growth analysis includes the study of China, Singapore, India, Japan, Australia & New Zealand, South Korea, Indonesia, and Rest of Asia-Pacific. The public healthcare system in the Republic of Korea is termed the National Health Insurance. It is offered to all citizens via the National Health Insurance Corporation, under the Ministry of Health and Wellness. As per a report issued by the World Health Organization (WHO), the Ministry of Health and Wellness undertakes the policy decisions, the operations of the National Health Insurance Program, and the supervision of the health system, as well.
In addition, the Ministry of Health also oversees and directs Medicare institutions in charge of delivering healthcare services in South Korea. Aligning with this, the MFDS published guidelines for the evaluation of companion diagnostics as well as corresponding therapeutics in the year 2018. Similarly, the MFDS also issued a more specific set of guidelines for the analysis of blood-based companion diagnostics with liquid biopsy. Hence, these factors are set to play a vital role in fueling the market growth in the Asia-Pacific over the forecast period.
COMPETITIVE INSIGHTS
Eminent enterprises operating in the market are Sysmex Corporation, ICarbonX, Amoy Diagnostics, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
'
1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations
2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview
3. Market Dynamics
3.1. Key Drivers
3.1.1. Growing Number Of Cancer Cases And Mortalities
3.1.2. Increasing Popularity Of Precision Medicines
3.1.3. Rising Number Of Adverse Drug Reaction Cases
3.2. Key Restraints
3.2.1. Country-specific Reimbursement Issues
3.2.2. Frequent Cases Of Leakage In Companion Diagnostics For Oncology
4. Key Analytics
4.1. Impact Of Covid-19 On Companion Diagnostics Market
4.2. Key Market Trends
4.3. Porter’s Five Forces Analysis
4.3.1. Buyers Power
4.3.2. Suppliers Power
4.3.3. Substitution
4.3.4. New Entrants
4.3.5. Industry Rivalry
4.4. Opportunity Matrix
4.5. Vendor Landscape
4.6. Value Chain Analysis
4.7. Key Buying Criteria
4.8. Regulatory Framework
5. Market By Technology
5.1. In Situ Hybridization
5.2. Polymerase Chain Reaction
5.3. Immunohistochemistry
5.4. Next Generation Sequencing
5.5. Other Technologies
6. Market By Indication
6.1. Oncology
6.2. Neurology
6.3. Infectious Diseases
6.4. Other Indications
7. Market By End-user
7.1. Pharmaceutical And Biopharmaceutical Companies
7.2. Reference Laboratories
7.3. Other End-users
8. Market By Products & Services
8.1. Assay Kits And Reagents
8.2. Software & Services
9. Geographical Analysis
9.1. Asia-pacific
9.1.1. Market Size & Estimates
9.1.2. Key Growth Enablers
9.1.3. Key Challenges
9.1.4. Key Players
9.1.5. Country Analysis
9.1.5.1. China
9.1.5.2. Japan
9.1.5.3. India
9.1.5.4. South Korea
9.1.5.5. Indonesia
9.1.5.6. Singapore
9.1.5.7. Australia & New Zealand
9.1.5.8. Rest Of Asia-pacific
10. Competitive Landscape
10.1. Key Strategic Developments
10.1.1. Mergers & Acquisitions
10.1.2. Product Launches & Developments
10.1.3. Partnerships & Agreements
10.2. Company Profiles
10.2.1. Abbott Laboratories
10.2.2. Agilent
10.2.3. Alamc Group
10.2.4. Arup Laboratories
10.2.5. Biocartis
10.2.6. Biomerieux Sa
10.2.7. Danaher Corporation
10.2.8. Ge Healthcare
10.2.9. Genomic Health
10.2.10. Illumina Inc
10.2.11. Myriad Genetics Inc
10.2.12. Qiagen Nv
10.2.13. Roche Diagnostics
10.2.14. Sysmex Corporation
10.2.15. Thermo Fisher Scientific Inc
